Navigation Links
Gen-Probe Reports Financial Results for Second Quarter 2009
Date:7/30/2009

n, compared to $7.1 million in the prior year period, a decrease of 45%.

Royalty and license revenues for the second quarter of 2009 were $1.5 million, compared to $1.5 million in the prior year period. For the first six months of 2009, royalty and license revenues were $3.5 million, compared to $20.1 million in the prior year period. As previously discussed, this significant decrease resulted primarily from $16.4 million of royalty and license revenue that was recorded in the first quarter of 2008 associated with the settlement of Gen-Probe's patent infringement litigation against Bayer. This revenue represented the third and final payment due in connection with the 2006 settlement of the companies' litigation.

Gross margin on product sales in the second quarter of 2009 was 67.3% on a non-GAAP basis that excludes $0.1 million of acquisition-related depreciation expense, compared to 71.4% in the prior year period. This decrease resulted primarily from the stronger U.S. dollar, the addition of Tepnel's generally lower-margin revenues, and the previously discussed $2.6 million payment in the prior year period related to historical revenue adjustments in the Novartis collaboration. For the first six months of 2009, gross margin on product sales was 68.8% on a non-GAAP basis that excludes $0.1 million of acquisition-related depreciation expense, compared to 69.7% in the prior year period. On a GAAP basis, gross margin on product sales was 67.2% in the second quarter of 2009, and 68.8% for the first six months of the year.

Acquisition-related intangible amortization expenses in each of the second quarter and first six months of 2009 were $1.1 million, compared to $0 in the comparable prior year periods.

Research and development (R&D) expenses in the second quarter of 2009 were $26.1 million, compared to $29.4 million in the prior year period, a decrease of 11%. This decrease resulted
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. Gen-Probe to Webcast Two Upcoming Investor Presentations
2. Gen-Probe Reports Financial Results for First Quarter 2009
3. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
4. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
5. Tepnel Shareholders Approve Acquisition by Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
7. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
8. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
9. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
10. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
11. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... For most families, fall means back-to-school ... patch or annual festival. For millions of children, fall ... the respiratory infection Enterovirus D68. , While symptoms ... percentage – especially children with weakened immune systems – ... Enterovirus is prompting hospitals across the country to enact ...
(Date:9/30/2014)... Tampa, FL (PRWEB) September 30, 2014 ... doors to two new clinics in Nashville, Tennessee. RMS ... Sleep Apnea Institute, and the expansion of a new ... the introduction of the Sleep Apnea Institute to Nashville, ... that suffer from sleep apnea: both diagnosed and undiagnosed. ...
(Date:9/30/2014)... 30, 2014 Two revolutionary procedures now being ... of gum disease a far less painful and far ... “If you’ve ever felt electric shock waves surge through your ... cold beverage, it’s possible you already know the impact of ... a general dentist in West Palm Beach, and a Fellow ...
(Date:9/30/2014)... (Sept. 30, 2014) Levothyroxine is considered the gold ... a new review of therapies for the condition ... altered that assessment, say a team of investigators.,1Their analysis, ... Thyroid , finds insufficient consistent data exist to ... generic, or sold under various trade names, such as ...
Breaking Medicine News(10 mins):Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... Plan Participation , , FALLS ... plan executives expect the current economic crisis to have a ... to a survey released today by CSC (NYSE: ... the Financial Crisis." While few expect immediate changes in enrollment ...
... (December 16, 2008) The Life Sciences Discovery ... Four Washington State-based research organizations will receive life ... The newly-funded health research initiatives will focus on ... resuscitation technology, improving the delivery of mental health ...
... a neurological disorder characterized by involuntary abnormal muscle constrictions. ... but the mechanism of abnormal muscle constrictions has not ... Prof Atsushi Nambu and Dr Satomi Chiken of National ... Pullanipally Shashidharan of Mt Sinai School of Medicine in ...
... VirtualHealth,Technologies, Inc. (OTC Bulletin Board: VHGI) the owners ... announced today,that it has appointed Anthony Bocchichio to its ... Mr. Bocchichio has over 37 years of experience in ... the Drug Enforcement Agency. He served,as both Assistant Special ...
... Cadence Pharmaceuticals, Inc.,(Nasdaq: CADX ) today ... III clinical trial of Acetavance(TM), the company,s intravenous,formulation ... following,abdominal laparoscopic surgery. Study 304 successfully met ... summed pain intensity,differences from baseline over 24 hours ...
... Guidenz , the medical information business unit of Cerebrio, ... OMC ), and MedLink International, Inc. (OTC Bulletin Board: MLKNA), ... and services that ease the accessibility of physicians and patients ... agreement to develop and market a suite of unique information ...
Cached Medicine News:Health News:Health Plan Executives Foresee Continued Decline in Small Business Enrollment, According to CSC Survey 2Health News:Health Plan Executives Foresee Continued Decline in Small Business Enrollment, According to CSC Survey 3Health News:Life Sciences Discovery awards health research program grants 2Health News:Life Sciences Discovery awards health research program grants 3Health News:Life Sciences Discovery awards health research program grants 4Health News:Life Sciences Discovery awards health research program grants 5Health News:VirtualHealth Technologies, Inc. Appoints Former DEA Assistant Administrator to its Advisory Board 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 3Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 4Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 5Health News:Cerebrio, LLC, an Omnicom Group Company, and MedLink International Undertake an Exclusive Development and Marketing Arrangement 2
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... Leading academic and industry specialists ... discuss the challenges that could see R&D grind to a ... Selecting and screening the correct polymorphs and ensuring ... effective way has never been more vital. According to George ...
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
Cached Medicine Technology:Pharma Industry Unites With Academia to Tackle Ongoing Problem 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: